We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Chief executive Paul Hudson sounds the alarm over British government’s cuts to research
US judge dismisses almost 2,500 lawsuits alleging links between heartburn medication and cancer
Change comes as French pharma group pours money into immunology and cancer research
Shares in French pharma group tumble nearly 6% after blow to pipeline of new treatments
Companies face thousands of pending personal injury cases linking Zantac to cancer
Pharma companies are hoping to catch up with rivals as they report promising trial results for jab
‘Next-generation’ jab delivers strong immune response against variants
Cross-section of companies want to ‘ensure laggards don’t delay the market shift’
Drugmakers to apply for protein-based shot to be used as primary and booster jabs
French pharma group still working on long-delayed Covid vaccine
French pharma group says jab will probably come to market in first quarter of 2022
French group says it is too late to market jab and is working on another with GSK using different technique
The acquisition is a sign of the French pharma group’s determination to get back on the podium
French pharma group tries to catch up with rivals that used the technology to create Covid vaccines
French group still aims for its Covid-19 jab to be approved by year end
French group to open a ‘dedicated mRNA centre of excellence’ after falling behind in Covid-19 jab race
Britain’s pension regulator says French drugmaker began talks after threat of enforcement action
UK group and France’s Sanofi release trial data of Covid jab showing strong immune response
French group has fallen behind newcomers despite being one of the biggest jab makers in world
New vaccine producers and mRNA technology are shaking up the market
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology
French vaccine maker aims to get a Covid-19 shot to market by the fourth quarter
Deal is latest in string of acquisitions that have given drugmaker access to new technologies
French group also weighs possibility of manufacturing rival Covid-19 vaccines
International Edition
